Is the use of RAS inhibitors safe in the current era of COVID-19 pandemic?

Sungha Park, Hae Young Lee, Eun Joo Cho, Ki Chul Sung, Juhan Kim, Dae Hee Kim, Sang Hyun Ihm, Kwang Il Kim, Il Suk Sohn, Wook Jin Chung, Hyeon Chang Kim, Sung Kee Ryu, Wook Bum Pyun, Jinho Shin

Research output: Contribution to journalReview articlepeer-review

15 Citations (Scopus)


Antihypertensive drugs are one of the most widely used pharmacologic agent in the world and it is predominantly used in the elderly subjects. Pneumonia is the most common cause of death in the extremely old subject. During infection and its complication such as sepsis, hypotension could be exacerbated by antihypertensive drugs because homeostasis mechanisms such as sodium balance, renin angiotensin aldosterone system and/or sympathetic nervous system can be mitigated by antihypertensive drug therapy. Severe Acute Respiratory Syndrome-Coronavirus-1 and 2 viral surface protein is known to attach angiotensin converting enzyme 2 (ACE2) on the cell membrane to facilitate viral entry into the cytoplasm. Despite the theoretical concerns of increased ACE2 expression by Renin-Angiotensin-Aldosterone system (RAS) blockade, there is no evidence that RAS inhibitors are harmful during COVID-19 infection and have in fact been shown to be beneficial in animal studies. Therefore, it is recommended to maintain RAS blockade during the current corona virus pandemic.

Original languageEnglish
Article number11
JournalClinical Hypertension
Issue number1
Publication statusPublished - 2020 May 7

Bibliographical note

Publisher Copyright:
© 2020 The Author(s).

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Is the use of RAS inhibitors safe in the current era of COVID-19 pandemic?'. Together they form a unique fingerprint.

Cite this